Higher line treatment of metastatic renal cell carcinoma


MUDr. Igor Richter, Ph.D.1,2,3; doc. MUDr. Josef Dvořák, Ph.D.2; MUDr. Vladimír Šámal, Ph.D.4; MUDr. Jiří Bartoš, MBA1

1 Onkologické oddělení, Krajská nemocnice Liberec

2 Onkologická klinika 1. LF UK a Fakultní Thomayerovy nemocnice, Praha

3 Fakulta zdravotnických studií, Technická univerzita v Liberci

4 Urologické oddělení, Krajská nemocnice Liberec



Targeted therapy and immunotherapy have improved survival outcomes for patients with metastatic renal cell carcinoma. ESMO, NCCN and Czech society for oncology provide some guidelines for the most appropriate first-, secondand third-line treatment. With the growing number of available therapeutic agents and improved survival, the optimal treatment patterns in fourth-line therapy need to be examined. No robust evidence exists to optimize treatment selection in this setting. The fourth-line therapy varies significantly amongst different centers and jurisdictions.


Key words

renal cell cancer, metastases, targeted therapy, immunotherapy, sequence of therapy, fourth-line therapy



The full article is only available to subscribers

Become a regular subscriber to our Oncological Review...